Email us for help
Allogeneic stem cell transplantation is the only curative option for patients battling acute myeloid leukemia. However, a significant number of patients will relapse after transplant. Innovative research and therapies are needed in order to improve outcomes in AML patients.
The drug Jakafi (ruxolitinib), a kinase inhibitor, is being explored in a current clinical trial as it may help reduce the risk of relapse. Other therapies such as pre-emptive donor lymphocyte infusions, hypomethylating agents and FLT3 inhibitors combined with donor lymphocyte infusions, CAR T-cell and CAR-NK cells are some of the options being explored.
Join us live on Wednesday, October 5th at 1:30 pm EST to hear from Dr. Gabriela Hobbs with Massachusetts General Hospital who will be discussing her clinical trial using Jakafi (ruxolitinib) after allogeneic stem cell transplant as well as other therapies to reduce relapse risk. There will be time at the end of the show to ask Dr. Hobbs your questions directly!
Thank you to our episode sponsor, Bristol Myers Squibb.